Re-printed today March 14, 2009 at the request of others who missed this posting when it first printed to this blog:
Information found here provided by: MS Views and News, Inc
Business Wire
March 3, 2009
JERUSALEM - (BUSINESS WIRE) - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for COPAXONE(®) (glatiramer acetate injection) to include the treatment of patients who have experienced a first clinical episode and have magnetic resonance imaging (MRI) features consistent with multiple sclerosis (MS).
The FDA’s approval follows a similar decision by the Medicines and Healthcare Products Regulatory Agency (MHRA) in February 2009 under which 24 EU member states have mutually recognized an expanded label for COPAXONE(® )to include the treatment of patients with clinically isolated syndrome (CIS) suggestive of MS. .
Have a Question, Comment or information for others? If so, please use the post comment link found below. Your name and email address would be appreciated but is not necessary unless you want a response from others. Thank You
============================================
0 comments:
Post a Comment